AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 8.01 |
Market Cap | 579.16M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.6 |
PE Ratio (ttm) | -14.77 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 9.7 |
Volume | 244,242 |
Avg. Volume (20D) | 377,475 |
Open | 9.18 |
Previous Close | 9.16 |
Day's Range | 8.84 - 9.31 |
52-Week Range | 3.90 - 14.38 |
Beta | undefined |
About BVS
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones,...
Analyst Forecast
According to 3 analyst ratings, the average rating for BVS stock is "Strong Buy." The 12-month stock price forecast is $15, which is an increase of 69.30% from the latest price.
Next Earnings Release
Analysts project revenue of $144.83M, reflecting a 6.95% YoY growth and earnings per share of 0.08, making a 14.29% increase YoY.